This week, nine pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc. (PATH) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

This week, Zoetis, Inc. Class A (ZTS) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. For more information, get Portfolio Grader’s complete analysis of ZTS stock.

Cempra, Inc. (CEMP) earns an A this week, jumping up from last week’s grade of B. Cempra manufactures and markets pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of CEMP stock.

This week, Salix Pharmaceuticals, Ltd. (SLXP) pushes up from a C to a B rating. Salix Pharmaceuticals acquires, develops and commercializes prescription drugs used to treat gastrointestinal diseases. For more information, get Portfolio Grader’s complete analysis of SLXP stock.

This week, Tetraphase Pharmaceuticals, Inc.’s (TTPH) ratings are up from a B last week to an A. For more information, get Portfolio Grader’s complete analysis of TTPH stock.

Watson Pharmaceuticals (WPI) boosts its rating from a B to an A this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

SciClone Pharmaceuticals, Inc.’s (SCLN) ratings are looking better this week, moving up to an A from last week’s B. SciClone Pharmaceuticals is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs. For more information, get Portfolio Grader’s complete analysis of SCLN stock.

CymaBay Therapeutics, Inc. (CBAY) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of CBAY stock.

This is a strong week for Sucampo Pharmaceuticals, Inc. Class A (SCMP). The company’s rating climbs to A from the previous week’s B. Sucampo Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. For more information, get Portfolio Grader’s complete analysis of SCMP stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.